

Trans #	Acquiring	Acquired	Entities
20071583 .....	William H. Gates, III .....	Dynegy Inc .....	CoGen Lyondell, LLC.
20071590 .....	News Corporation .....	Photobucket.com, Inc .....	Photobucket.com, Inc.
20071593 .....	Kellwood Company .....	Hanna Andersson Corporation .....	Hanna Andersson Corporation.
20071597 .....	Perry Partners International, Inc .....	Universal American Financial Corp ..	Universal American Financial Corp.
20071598 .....	Perry Partners, L.P .....	Universal American Financial Corp ..	Universal American Financial Corp.
20071601 .....	Pro Acquisition Corporation .....	The Home Depot, Inc .....	CND Holdings, Inc., HD Supply, Inc., Homer TLC, Inc.
20071607 .....	TD AMERITRADE Holding Corpora- tion.	Fiserv, Inc .....	Fiserv Trust Company.

**Transactions Granted Early Termination—07/03/2007**

20070837 .....	Hanover Compressor Company .....	Universal Compression Holdings, Inc	Universal Compression Holdings, Inc.
20070838 .....	Universal Compression Holdings, Inc	Hanover Compressor Company .....	Hanover Compressor Company.
20071506 .....	KASLION S.a.r.L .....	DSP Group Inc .....	DSP Group Inc.
20071511 .....	J&F Participacoes S.A .....	Hicks, Muse, Tate & Furst Equity Fund V, L.P.	Swift Foods Company.
20071588 .....	Cleveland-Cliffs Inc .....	PinnOak Resources, LLC .....	PinnOak Resources, LLC.
20071599 .....	C/R Stallion Investment Partnership, L.P.	Terry G. Bailey .....	Salty's Manufacturing, Ltd., Salty's Well Hill No. 1, Ltd., Salty's Well Parker No. 1, Ltd., Salty's Well Service, Ltd.
20071602 .....	C/R Stallion Investment Partnership, L.P.	Envirovac, Ltd .....	Salty's Manufacturing, Ltd., Salty's Well Hill No. 1, Ltd., Salty's Well Johnson No. 1, Ltd., Salty's Well Johnson No. 2, Ltd., Salty's Well Johnson No. 3, Ltd., Salty's Well Johnson No. 4, Ltd., Salty's Well Nacogdoches 1, Ltd., Salty's Well Panola 1, Ltd., Salty's Well Parker No. 1, Ltd., Salty's Well Service, Ltd., Salty's Well Shelby No. 1, Ltd.

**Transactions Granted Early Termination—07/05/2007**

20071519 .....	Carlyle Partners IV, L.P .....	JP Morgan Chase & Co .....	Niagara Holdings, Inc.
----------------	--------------------------------	----------------------------	------------------------

**Transactions Granted Early Termination—07/06/2007**

20071520 .....	Saudi Basic Industries Corporation ...	General Electric Company .....	GE Entities.
----------------	--	--------------------------------	--------------

**FOR FURTHER INFORMATION CONTACT:**

Sandra M. Peay, Contact Representative, or Renee Hallman, Contact Representative. Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room H-303, Washington, DC 20580, (202) 326-3100.

By direction of the Commission.

**Donald S. Clark,**

*Secretary.*

[FR Doc. 07-3435 Filed 7-13-07; 8:45 am]

**BILLING CODE 6750-01-M**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Office of the Secretary**

**Findings of Misconduct in Science**

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case:

*Kristin Roovers, Ph.D., University of Pennsylvania:* Based on an investigation conducted by the University of Pennsylvania (UP) and additional analysis and information obtained by the Office of Research Integrity during its oversight review, the U.S. Public Health Service (PHS) found that Kristin Roovers, Ph.D., former postdoctoral fellow, Departments of Medicine, Cell and Developmental Biology, and Pharmacology, and Howard Hughes Medical Institute, and former graduate student, Department of Pharmacology, UP, engaged in misconduct in science in research funded by National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), grants R01 HL061567, P50 HL057278, and T32 HL07873, National Institutes of Diabetes and Digestive and Kidney

Diseases (NIDDK), NIH, grants P30 DK52574 and R01 DK066886, National Cancer Institute (NCI), NIH, grant R01 CA72639, and National Institute of General Medical Sciences (NIGMS), NIH, grants R01 GM48224, R01 GM58224, R01 GM51878, and R01 GM69064.

Dr. Roovers' manipulations and falsification of data were extensive, encompassing 19 panels of Western blot data, appearing in 11 figures in 3 publications from her research as a graduate student and her first postdoctoral position and in 9 panels of immunoblot data in 8 figures of an unpublished manuscript.

Specifically, the findings involved falsification by duplication and reuse of immunoblot data to misrepresent the results as data from different experiments that had been reported in the following manuscript and three publications:

- Figures 2C, 3C, 4D, 4E, 6C, 7B, and supplement Figures 1, 2B, and 3B in a

manuscript submitted to the *Journal of Clinical Investigation* entitled: "Akt1 promotes physiologic, but antagonizes pathologic, cardiac growth."

- Figures 3A, 3C, and 4A in: Welsh, C.F., Roovers, K., Villanueva, J., Liu, Y., Schwartz, M.A., & Assoian, R.K.

"Timing of cyclin D1 expression within G1 phase is controlled by Rho." *Nature Cell Biology* 3(11):950–957, 2001.

- Figures 1, 2A, 2B, 3A, 3C, 4A, 4B, 6C, 6D, and 6E in: Roovers, K., & Assoian, R.K.

"Effects of rho kinase and actin stress fibers on sustained extracellular signal-regulated kinase activity and activation of G(1) phase cyclin-dependent kinases." *Mol. Cell Biol.* 23(12):4283–4294, 2003. Retracted in *Mol. Cell Biol.* 26(13):5203, July 2006.

- Figures 1C, 2C, 5B, 5D, 6B and 6D in: Roovers, K., Klein, E.A., Castagnino, P., & Assoian, R.K. "Nuclear translocation of LIM kinase mediates Rho-Rho kinase regulation of cyclin D1 expression." *Developmental Cell* 5(2):273–284, 2003. Retracted in *Developmental Cell* 10(5):681, May 2006.

Corrections were recommended by UP for the *Nature Cell Biology* paper.

Dr. Roovers' falsified Western blot data from the publications in *Nature Cell Biology* and from *Developmental Cell* were included in NIH grant applications CA 72639–07 and GM 69064–01.

ORI has implemented the following administrative actions for a period of five (5) years, beginning on June 7, 2007:

(1) Dr. Roovers is debarred from eligibility for any contracting or

subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as "covered transactions" as defined in HHS' implementation of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension at 2 CFR part 376, *et seq.*; and

(2) Dr. Roovers is prohibited from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

**FOR FURTHER INFORMATION CONTACT:** Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800.

**Chris B. Pascal,**

*Director, Office of Research Integrity.*

[FR Doc. E7–13703 Filed 7–13–07; 8:45 am]

**BILLING CODE 4150–31–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

[30Day–07–06BM]

**Agency Forms Undergoing Paperwork; Reduction Act Review**

The Centers for Disease Control and Prevention (CDC) publishes a list of

**ESTIMATED ANNUALIZED BURDEN HOURS**

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hours)
Women Seeking Health Care Services .....	Eligibility Script for Pretest .....	70	1	1/60
	Baseline Questionnaire for Pretest .....	65	1	15/60
	Follow-up Questionnaire Pretest .....	59	1	12/60
	Eligibility Script for Main Study .....	1,533	1	1/60
	Baseline Questionnaire for Main Study .....	1,227	1	17/60
	Follow-up Questionnaire Main Study .....	860	1	22/60

Dated: July 9, 2007.

**Maryam I. Daneshvar,**

*Acting Reports Clearance Officer, Centers for Disease Control and Prevention.*

[FR Doc. E7–13730 Filed 7–13–07; 8:45 am]

**BILLING CODE 4163–18–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Substance Abuse and Mental Health Services Administration**

**Agency Information Collection Activities: Submission for OMB Review; Comment Request**

Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under

information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Officer at (404) 639–5960 or send an e-mail to: [omb@cdc.gov](mailto:omb@cdc.gov). Send written comments to CDC Desk Officer, Office of Management and Budget, Washington, DC or by fax to (202) 395–6974.

**Notice of Correction**

*Title of Project*

Randomized Controlled Trial of Routine Screening for Intimate Partner Violence—New—National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention (CDC).

**Description of Correction**

A 30-day **Federal Register** Notice was published on June 25, 2007 (Vol. 72, No. 121, pp. 34691–34692) describing proposed activities with total estimated annualized burden of 717.7 hours. The annualized total burden hour estimate is correct, however, due to a clerical oversight, the table of Estimated Annualized Burden Hours contained non-annualized figures for the Number of Respondents (i.e., project totals). The corrected table appears below. The total estimated annualized burden hours are 717.7.

OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (240) 276–1243.

**Project: National Evaluation of the Protection and Advocacy for Individuals with Mental Illness (PAIMI) Program—NEW**

In recognition that systematic evaluation of this and other government programs are part of good management